Continuous Manufacturing Market Key Highlights and Future

For decades, pharmaceutical companies have been using batch processing method for drug manufacturing, wherein a specific quantity of a drug is produced through multiple sequential steps.

The global continuous manufacturing market size is estimated to be worth USD 2,080 million in 2023 and anticipated to grow at a CAGR of 6.4% during the forecast period.

Presently, close to 60 manufacturers have adopted continuous manufacturing for single or multiple unit operations. Various types of biologics, including antibodies, enzymes, proteins / peptides, vaccines and viral vectors can be synthesized utilizing continuous manufacturing technique. It is worth noting that close to 75% of the continuous biologic manufacturers offer contract manufacturing services for continuous manufacturing of the above mentioned biologics.

Close to 700 patents related to continuous manufacturing have been filed by / granted to various organizations in order to protect the intellectual property. The increasing interest of industry and non-industry stakeholders in continuous manufacturing of small molecules and biologics has led to the expansion of intellectual capital in this domain. There has been a steady increase in the number of patents filed / granted, which indicates continuous research in this domain. This can be attributed to the several advantages offered by continuous manufacturing over conventional batch manufacturing, including the need for smaller facility space, reduced cost of production, low risk of contamination and continuous monitoring utilizing process analytical technology (PAT).

Majority of the patents filed in this domain are patent applications (67%), followed by those which have been granted approval (23%). Further, majority of the patents (82%) were filed / granted by industry players, followed by non-industry players. Moreover, despite the large number of patents that have been filed recently (and hence having a long remaining patent life), only 1% of the total patents have the highest relative valuation.

The continuous biologics manufacturing market is likely to grow at a cagr of ~9% over the next decade; driven by revenues generated from continuous upstream bioprocessing. As per the base case forecast scenario, the biologic continuous manufacturing market is estimated to grow at an annualized rate of ~9%, during the period 2023 to 2035. This opportunity will likely be well distributed across purpose of manufacturing, type of product manufactured, stage of bioprocessing, scale of operation, company size and key geographical regions.

It is worth mentioning that according to our projections, the markets in Europe are likely to capture majority (40%) of the overall biologic continuous manufacturing market, and this trend is unlikely to change in the future, as well. It is worth highlighting that the market in Asia-Pacific is expected to grow at a higher CAGR as compared to other regions in the coming years.

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Continuous Manufacturing Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To get sample report visit@

https://www.rootsanalysis.com/reports/continuous-manufacturing/request-sample.htm